The Portnoy Law Firm announced the commencement of a class action lawsuit for investors of Medpace Holdings, Inc. This notice pertains to individuals who purchased securities from April 22, 2025, to February 9, 2026. Investors are urged to take action before the June 8, 2026, deadline to file a lead plaintiff motion.
Class Action Details for Medpace Holdings Investors
Lesley F. Portnoy, the lead attorney at the Portnoy Law Firm, encourages affected investors to reach out for assistance. Legal representatives can connect via phone at 310-692-8883 or email at [email protected] Potential claimants can also join the case through the firm’s website.
Background on Medpace Holdings
Medpace Holdings, Inc. is a prominent clinical contract research organization (CRO). The company offers outsourced clinical development services tailored for the biotechnology, pharmaceutical, and medical device sectors. The class action lawsuit alleges that Medpace misrepresented several key business metrics during the specified class period.
Key Allegations against Medpace
- Medpace overstated its projected book-to-bill ratio for the fourth quarter of 2025.
- The company failed to acknowledge the detrimental impact of cancellations on its book-to-bill ratio.
- Medpace insisted that its guidance of a 1.15 book-to-bill ratio was achievable, despite indications of a weak business environment.
- Management assured investors regarding the lack of diversity in the pre-backlog, minimizing concerns.
- Despite growth in metabolic studies, management claimed the company’s success wasn’t limited to only a few projects.
Impact of Earnings Announcement
On February 9, 2026, Medpace released its earnings results for the fourth quarter of 2025. The results showed a disappointing book-to-bill ratio of 1.04, which fell short of its earlier guidance. Following this announcement, Medpace’s stock price plummeted by nearly 16%.
Legal Assistance for Affected Investors
The Portnoy Law Firm specializes in representing investors seeking to recover losses incurred from corporate misconduct. The firm’s founding partner has successfully recovered over $5.5 billion for clients in previous cases. A courtesy case evaluation is available for potential claimants to discuss their rights and options moving forward.
For those affected by the alleged wrongdoing of Medpace Holdings, swift action is recommended to ensure participation in the class action.
